🟢 Arcturus Therapeutics is trading 6.68% up in after-hours trading on positive interim ARCT-810 Phase 2 results

Arcturus Therapeutics is trading 6.68% higher at $14.19 after reporting positive interim Phase 2 results for ARCT-810, its investigational mRNA therapy for OTC deficiency.

• The treatment showed favorable disease-related biomarker activity, including normalized ammonia levels.
• The company scheduled a presentation on September 23, 2026, at 4:30 p.m. ET, covering the data and its mRNA liver-therapeutics platform.
• The gain contrasts with the broader market decline, with the company-specific clinical update the clearest catalyst.